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I. Materials and Methods 
 
 Unless otherwise noted, all chemicals and reagents for chemical reactions were 
obtained from commercial suppliers (Sigma-Aldrich, Acros) and used without further 
purification. The following heme proteins were all purchased from Sigma-Aldrich: 
myoglobin (from equine heart), peroxidase II (from horseradish), cytochrome c (from 
bovine heart), catalase (from Corynebacterium glutamicum) and chloroperoxidase (from 
Caldariomyces fumago). Silica gel chromatography purifications were carried out using 
AMD Silica Gel 60, 230-400 mesh. 1H and 13C NMR spectra were recorded on either a 
Varian Mercury 300 spectrometer (300 MHz and 75 MHz, respectively), or a Varian 
Inova 500 MHz (500 MHz and 125 MHz, respectively), and are internally referenced to 
residual solvent peak. Data for 1H NMR are reported in the conventional form: chemical 
shift (δ ppm), multiplicity (s=singlet, d=doublet, t=triplet, q=quartet, m=multiplet, 
br=broad), coupling constant (Hz), integration. Data for 13C are reported in terms of 
chemical shift (δ ppm) and multiplicity. High-resolution mass spectra were obtained with 
a JEOL JMS-600H High Resolution Mass Spectrometer at the California Institute of 
Technology Mass Spectral Facility. Reactions were monitored using thin layer 
chromatography (Merck 60 silica gel plates) using an UV-lamp for visualization. Optical 
rotation was measured using a JASCO P-2000 Polarimeter.  
 Gas chromatography (GC) analyses were carried out using a Shimadzu GC-17A 
gas chromatograph, a FID detector, and J&W scientific cyclosil-B columns (30 m x 0.32 
mm, 0.25 µm film and 30 m x 0.25 mm, 0.25 µm film). High-performance liquid 
chromatography (HPLC) was carried out using an Agilent 1200 series, an UV detector, 
and an Agilent XDB-C18 column (4.6 x 150 mm, 5 µm). Cyclopropane product standards 
for the reaction of ethyl diazoacetate (EDA) with styrene (ethyl 2-phenylcyclopropane-1-
carboxylate) and α-methylstyrene (ethyl 2-methyl-2-phenylcyclopropane-1-carboxylate) 
were prepared as reported (18). These standards and enzyme-prepared cyclopropanes 
demonstrated identical retention times in gas chromatograms when co-injected, 
confirming product identity. Absolute stereoconfiguration of cyclopropane enantiomers 
was determined by measuring optical rotation of purified cyclopropane products from 
preparative bioconversion reactions using enantioselective P450-BM3 variants and 
referenced to values taken from reference (19). Authentic P450-catalyzed cyclopropane 
samples were also prepared as described in section VIII and were characterized by NMR 
(1H and 13C) and mass spectrometry. 
 Plasmids pCWori[BM3] and pET22 were used as cloning vectors. Site-directed 
mutagenesis was accomplished by standard overlap mutagenesis using primers bearing 
desired mutations (IDT, San Diego, CA). Primer sequences are available upon request. 
Electrocompetent Escherichia coli cells were prepared following the protocol of 
Sambrook et al. (20). Restriction enzymes BamHI, EcoRI, XhoI, Phusion polymerase, 
and T4 ligase were purchased from New England Biolabs (NEB, Ipswich, MA). Alkaline 
phosphatase was obtained from Roche (Nutley, NJ). The 1,000x trace metal mix used in 
expression cultures contained: 50 mM FeCl3, 20 mM CaCl2, 10 mM MnSO4, 10 mM 
ZnSO4, 2 mM CoSO4, 2 mM CuCl2, 2 mM NiCl2, 2 mM Na2MoO4, and 2 mM H3BO3.   
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II.  General Procedures 
 
Enzyme library screening. Libraries maintained in our laboratory are stored at -78 °C as 
glycerol stocks (Luria-Bertani medium (LBamp), 150 µL, 25% v/v glycerol with 0.1 mg 
mL-1 ampicillin) in 96-well plates. These stocks were used to inoculate 96-shallow-well 
plates containing 300 µL LBamp medium using a 96-pin stamp. Single colonies from site-
saturation libraries were picked with toothpicks and used to inoculate 300 µL of LBamp. 
The cells were incubated at 37 °C, 250 rpm shaking, and 80% relative humidity 
overnight. After 16 h, 50 µL aliquots of these overnight cultures were transferred into 2 
mL, deep-well plates containing terrific broth (TBamp) (800 µL containing 0.1 mg mL-1 
ampicillin, 1 µL mL-1 trace metal mix and 20 mg L-1 aminolevulinic acid) using a 
Multimek 96-channel pipetting robot (Beckman Coulter, Fullerton, CA). The cultures 
were incubated at 37 °C for 3 h and 30 min, and 30 min after reducing the incubation 
temperature to 25 °C (250 rpm, 80% relative humidity), 50 µL isopropyl β-D-1-
thiogalactopyranoside (IPTG, 4.5 mM in TBamp) was added, and the cultures were 
allowed to continue for another 24 h at 25 °C (250 rpm, 80% relative humidity). Cells 
were then pelleted (3,000xg, 15 min, 4 °C) and stored at -20 °C until further use, but at 
least for 2 h. For cell lysis, plates were allowed to thaw for 30 min at room temperature 
and then cell pellets were resuspended in 275 µL phosphate buffer (0.1 M, pH = 8.0, 0.65 
mg mL-1 lysozyme, 10 mM magnesium chloride and 40 U mL-1 DNAse I). The lysing 
cells were incubated at 37 °C for 1 h. Cell debris was separated by centrifugation at 
5,000xg and 4 °C for 15 min. The resulting crude lysates were then transferred to 96-well 
microtiter plates for CO assays and to 2 mL deep-well plates for bioconversions. 
 
CO binding assay. Na2S2O4 (160 µL, 0.1 M in phosphate buffer, 0.1 M, pH = 8.0) was 
added to P450BM3 variants in cell lysate (40 µL). The absorbance at 450 and 490 nm was 
recorded using a Tecan M1000 UV/Vis plate reader, and the microtiter plates were placed 
in a vacuum chamber. The chamber was sealed, evacuated to approximately - 15 in Hg, 
purged with CO gas, and incubated for 30 min. The plates were then removed and the 
absorbance at 450 and 490 nm was again recorded using a plate reader. The difference 
spectra could then be used to determine the P450 concentration in each well as previously 
described (21).  
 
P450 expression and purification. For the enzymatic transformations, P450BM3 variants 
were used in purified form. Enzyme batches were prepared as follows. One liter TBamp 
was inoculated with an overnight culture (100 mL, LBamp) of recombinant E. coli DH5α 
cells harboring a pCWori plasmid encoding the P450 variant under the control of the tac 
promoter. After 3.5 h of incubation at 37 °C and 250 rpm shaking (OD600 ca. 1.8), the 
incubation temperature was reduced to 25 °C (30 min), and the cultures were induced by 
adding IPTG to a final concentration of 0.5 mM. The cultures were allowed to continue 
for another 24 hours at this temperature. After harvesting the cells by centrifugation (4 
°C, 15 min, 3,000xg), the cell pellet was stored at -20 °C until further use but at least for 
2 h. The cell pellet was resuspended in 25 mM Tris.HCl buffer (pH 7.5 at 25 °C) and 
cells were lysed by sonication (2x1 min, output control 5, 50% duty cycle; Sonicator, 
Heat Systems - Ultrasonic, Inc.). Cell debris was removed by centrifugation for 20 min at 
4 °C and 27,000xg and the supernatant was subjected to anion exchange chromatography 
	  
 
 5	  
on a Q Sepharose column (HiTrapTM Q HP, GE Healthcare, Piscataway, NJ) using an 
AKTAxpress purifier FPLC system (GE healthcare). The P450 was eluted from the Q 
column by running a gradient from 0 to 0.5 M NaCl over 10 column volumes (P450 
elutes at 0.35 M NaCl). The P450 fractions were collected and concentrated using a 30 
kDa molecular weight cut-off centrifugal filter and buffer-exchanged with 0.1 M 
phosphate buffer (pH = 8.0). The purified protein was flash-frozen on dry ice and stored 
at -20 °C. P450 concentration was determined in triplicate using the CO binding assay 
described above (10 µL P450 and 190 µL 0.1 M phosphate buffer, pH 8.0, per well).  
 
Thermostability measurements. Duplicate measurements were taken for all values 
reported on Tables S10 and S11.  Purified P450 solutions (4 µM, 200 µL) were heated in 
a thermocycler (Eppendorf) over a range of temperatures (38 °C - 65 °C) for 10 min 
followed by rapid cooling to 4 °C for 1 min. The precipitate was removed by 
centrifugation. The concentration of folded P450 remaining in the supernatant was 
measured by CO-difference spectroscopy (as described above). The temperature at which 
half of the protein was denatured (T50) was determined by fitting the data to the equation: 
f (T) = 100 / (1 + exp(a*(T – T50))).  
 
Typical procedure for small-scale cyclopropanation bioconversions under anaerobic 
conditions. Small-scale reactions (400 µL) were conducted in 2 mL crimp vials (Agilent 
Technologies, San Diego, CA). P450 solution (80 µL, 100 µM) was added to the vial 
with a small stir bar before crimp sealing with a silicone septum. Phosphate buffer (260 
µL, 0.1 M, pH = 8.0) and 40 µL of a solution of the reductant (100 mM Na2S2O4, or 20 
mM NADPH) were combined in a larger crimp-sealed vial and degassed by bubbling 
argon through the solution for at least 5 min (Fig S1). In the meantime, the headspace of 
the 2 mL reaction vial with the P450 solution was made anaerobic by flushing argon over 
the protein solution (with no bubbling). When multiple reactions were conducted in 
parallel, up to 8 reaction vials were degassed in series via cannulae. The buffer/reductant 
solution (300 µL) was syringed into the reaction vial, while under argon. The gas lines 
were disconnected from the reaction vial before placing the vials on a plate stirrer. A 40x 
styrene solution in MeOH (10 µL, typically 1.2 M) was added to the reaction vial via a 
glass syringe, and left to stir for about 30 s. A 40x EDA solution in MeOH was then 
added (10 µL, typically 400 mM) and the reaction was left stirring for the appropriate 
time. The final concentrations of the reagents were typically: 30 mM styrene, 10 mM 
EDA, 10 mM Na2S2O4, 20 µM P450.   
The reaction was quenched by adding 30 µL HCl (3M) via syringe to the sealed 
reaction vial. The vials were opened and 20 µL internal standard (20 mM 2-
phenylethanol in MeOH) was added followed by 1 mL ethyl acetate. This mixture was 
transferred to a 1.8 mL eppendorf tube which was vortexed and centrifuged (16,000xg, 1 
min). The top organic layer was dried over an anhydrous sodium sulfate plug and 
analyzed by chiral phase GC. 
 A slightly modified work-up was implemented for kinetic experiments. The 
reactions were quenched after the set time by syringing 1 mL EtOAc to the closed vials 
and immediately vortexing the mixture. The vials were then opened and 20 µL internal 
standard was added. The mixture was transferred to a 1.8 mL eppendorf tube, vortexed 
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and centrifuged (16,000xg, 1 min). The top organic layer was dried over an anhydrous 
sodium sulfate plug and analyzed by GC.  
 
Typical procedure for preparative-scale cyclopropanation bioconversions under 
anaerobic conditions. The P450 solution was added to a Schlenk flask with a stir bar. 
With the flask kept on ice, the head-space was evacuated and back-filled with argon (4 x) 
with care not to foam the protein solution. Phosphate buffer and reductant were pre-
mixed and degassed together in a separate round-bottom-flask by bubbling argon through 
the solution for 20 min. The buffer/reductant solution was transferred to the Schlenk flask 
via syringe. Styrene was added under argon and left to mix for 1 min. EDA was added 
dropwise under argon. The solution was left to stir under argon until reaction completion. 
The reaction was quenched under argon by adding hydrochloric acid (3 M) to adjust the 
pH to 4, before opening the Schlenk flask. The reaction mixture was stirred with sodium 
chloride and dichloromethane (CH2Cl2). The combined emulsion layers were then filtered 
through Celite to break the emulsion and the Celite pad was rinsed with 3x20 mL 
CH2Cl2. The resulting biphasic mixture was transferred to a separating funnel and the 
organic phase was removed. The remaining aqueous phase was re-extracted with 3x40 
mL CH2Cl2. The combined organic extracts were dried with sodium sulfate, filtered, and 
concentrated. The resulting residue was purified by SiO2 chromatography.  
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III. Preliminary Experiments with Heme Proteins 
 
The following six heme proteins were initially screened for cyclopropanation activity: 
catalase, chloroperoxidase (CPO), horseradish peroxidase (HRP), cytochrome C (cyt c), 
myoglobin (Mb) and P450BM3. Small-scale (400 µL) reactions were conducted as 
described in section II and were analyzed by GC (cyclosil-B 30 m x 0.25 mm x 0.25 µm): 
oven temperature = 130 °C.    
 
 
 
Table S1: Heme catalysts under anaerobic conditions with sodium dithionite 
(Na2S2O4)  
catalyst axial ligand cat. loading (% mol eq) TTN cis : trans*
 %ee cis† %ee trans‡ 
catalase O-Tyr 0.16 0 - - - 
CPO§ S-Cys 0.40 0 - - - 
HRP N-His 1.00 9 7 : 93 8 -7 
cyt c N-His, S-Met 1.00 19 6 : 94 0 12 
Mb N-His 1.00 43 6 : 94 -1 2 
P450BM3 S-Cys 0.20 5 37 : 63 -27 -2 
hemin - 0.20 73 6 : 94 -1 0 
 
* Diastereomeric ratios and enantiomeric excess were determined by GC analysis. †	  (R,S) 
– (S,R). ‡ (R,R) – (S,S). § Bioconversion conducted at 0.1 M citrate buffer pH = 4.0.   
 
 
 
 
 
 
 
 
 
 
 
 
OEt
O
N
N
+ + catalyst
0.1 M KPi pH 8.0
5% MeOH
10 mM Na2S2O4
30 mM 10 mM
Anaerobic
Ph COOEt Ph COOEt
SSS R
COOEt
R R
Ph
R S
COOEtPh
+
cis trans
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Table S2: Heme catalysts under anaerobic conditions without Na2S2O4   
catalyst axial ligand cat. loading (% mol eq) TTN cis : trans*
 %ee cis† %ee trans‡ 
catalase O-Tyr 0.16 0 - - - 
CPO§ S-Cys 0.40 0 - - - 
HRP N-His 1.00 0 - - - 
cyt c N-His, S-Met 1.00 12 8 : 92 8 -3 
Mb N-His 1.00 0.8 11 : 89 -2 8 
P450BM3 S-Cys 0.20 0 0 - - 
hemin - 0.20 4 11 : 89 -1 3 
 
* Diastereomeric ratios and enantiomeric excess were determined by GC analysis. †	  (R,S) 
– (S,R). ‡ (R,R) – (S,S). § Bioconversion conducted at 0.1 M citrate buffer pH = 4.0.   
 
 
 
 
 
 
 
 
Table S3: Heme catalysts under aerobic conditions with Na2S2O4  
catalyst axial ligand cat. loading (% mol eq) TTN cis : trans*
 %ee cis† %ee trans‡ 
catalase O-Tyr 0.16 0 - - - 
CPO§ S-Cys 0.40 0 - - - 
HRP N-His 1.00 1 12 : 88 -3 -7 
cyt c N-His, S-Met 1.00 3 9 : 91 -6 16 
Mb N-His 1.00 6 7 : 93 -13 12 
P450BM3 S-Cys 0.20 1 13 : 87 -38 -8 
hemin - 0.20 6 8 : 92 -5 1 
 
* Diastereomeric ratios and enantiomeric excess were determined by GC analysis. †	  (R,S) 
– (S,R). ‡ (R,R) – (S,S). § Bioconversion conducted at 0.1 M citrate buffer pH = 4.0.   
OEt
O
N
N
+ + catalyst
0.1 M KPi pH 8.0
5% MeOH
30 mM 10 mM
Anaerobic
Ph COOEt Ph COOEt
SSS R
COOEt
R R
Ph
R S
COOEtPh
+
cis trans
OEt
O
N
N
+ + catalyst
30 mM 10 mM
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Ph COOEt Ph COOEt
SSS R
COOEt
R R
Ph
R S
COOEtPh
+
cis trans
0.1 M KPi pH 8.0
5% MeOH
10 mM Na2S2O4
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Table S4: Heme catalysts under aerobic conditions without Na2S2O4 
catalyst axial ligand cat. loading 
(% mol eq) 
TTN cis : trans* %ee cis† %ee trans‡ 
catalase O-Tyr 0.16 0 - - - 
CPO§ S-Cys 0.40 0 - - - 
HRP N-His 1.00 0 - - - 
cyt c N-His, S-Met 1.00 0 - - - 
Mb N-His 1.00 0 - - - 
P450BM3 S-Cys 0.20 0.4 46 : 54 -46 36 
hemin - 0.20 0 - - - 
 
* Diastereomeric ratios and enantiomeric excess were determined by GC analysis. †	  (R,S) 
– (S,R). ‡ (R,R) – (S,S). § Bioconversion conducted at 0.1 M citrate buffer pH = 4.0.   
   
  
OEt
O
N
N
+ + catalyst
0.1 M KPi pH 8.0
5% MeOH
30 mM 10 mM
Aerobic
Ph COOEt Ph COOEt
SSS R
COOEt
R R
Ph
R S
COOEtPh
+
cis trans
	  
 
 10	  
 
IV. Screening P450BM3 variants for cyclopropanation activity 
 
Lysate screening under aerobic conditions. The 92 variants in our compilation plate 
(Table S5, following pages) represent a diverse selection of P450BM3 variants that have 
previously been engineered for monooxygenase activity on a variety of substrates, 
including but not limited to short alkane hydroxylation, demethylation of protected 
monosaccharides, and oxidation of lead drug compounds. These P450BM3 variants carry 
various mutations accumulated along sequential rounds of engineering efforts for activity 
towards the target substrates (Table S5) or were generated by recombination with 
homologous enzymes (Table S6). The compilation plate was expressed and lysed as 
described in section II (enzyme library screening). 150 µL lysate was transferred 
(Multimek 96-channel pipetting robot, Beckman Coulter, Fullerton, CA) to a 2 mL deep-
well plate, with 50 µL of 120 mM Na2S2O4 in 0.1 M KPi (pH = 8.0). 100 µL of a 30 mM 
styrene, 60 mM EDA mixed solution in 15% MeOH in 0.1 M KPi (pH = 8.0) was added 
to the plate to initiate the reaction. The plate was sealed and was left shaking (300 rpm) 
for four hours. The plastic seal was removed and 30 µL HCl (3 M) was added to quench 
the reaction followed by 20 µL of an internal standard solution (20 mM α-methylstyrene 
in methanol). The reactions were extracted by adding 500 µL EtOAc and carefully 
vortexing the plate. The plate was centrifuged (1,700xg) to separate the biphasic mixture. 
The top organic layer was transferred (2 x 150 µL) to a separate deep-well plate. The 
extracts for each of the 92 reactions were dried through 92 separate anhydrous sodium 
sulfate plugs. The dried extracts were analyzed by GC (cyclosil-B 30 m x 0.32 mm x 0.25 
µm): oven temperature = 60 °C 3 min, 7.5 °C / min   to 160 °C, 20 °C / min to 250 °C, 
250 °C 2 min, cis-cyclopropanes (20.3 min and 20.45 min), trans-cyclopropanes (21.8 
min). The top 10 protein variants of importance with respect to this report are highlighted 
in tables S5 and S6. 
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Table S5: Raw data from P450BM3 compilation plate screen 
 
Diastereo- and enantioselectivity were determined by gas chromatography using a chiral 
β-CDX column as the stationary phase.  
 
P450BM3 variant 
mutations with respect to 
wild-type P450BM3 
absolute 
activity* de
† ee (cis) ‡ 
CYP102A3 N/A 0.004053 -74 -8 
CYP102A2 N/A 0.002963 -76 -36 
CYP102A1 
(P450BM3) 
None 0.002240 -81 7 
WT F87A F87A 0.001704 -28 57 
WT T88L T88L 0.004522 -78 23 
WT A328V A328V 0.000830 -100 N/A 
J (22) 
V78A, T175I, A184V, F205C, 
S226R, H236Q, E252G, 
R255S, A290V, L353V 
0.001334 -100 N/A 
139-3 (23) 
V78A, H138Y, T175I, V178I, 
A184V, F205C, S226R, 
H236Q, E252G, R255S, 
A290V, L353V 
0.001386 -86 0 
9-10A (22) 
R47C, V78A, K94I, P142S, 
T175I, A184V, F205C, S226R, 
H236Q, E252G, R255S, 
A290V, L353V 
0.004292 -74 -20 
9-10A L75W 
(24) 9-10A L75W 0.005191 -83 -8 
9-10A L75I (24) 9-10A L75I 0.002267 -85 -3 
9-10A A78F (24) 9-10A L78F 0.002008 -82 -35 
9-10A A78S (24) 9-10A A78S 0.005098 -81 -6 
9-10A A82G (24) 9-10A A82G 0.002245 -76 -7 
9-10A A82F (24) 9-10A A82F #VALUE! N/A N/A 
9-10A A82C (24) 9-10A A82C 0.002487 -74 16 
9-10A A82I (24) 9-10A A82I 0.001031 -100 N/A 
9-10A A82S (24) 9-10A A82S 0.001483 -82 14 
9-10A A82L (22) 9-10A A82L 0.000591 -100 N/A 
9-10A F87A 9-10A F87A 0.001701 -61 -10 
9-10A F87V (24) 9-10A F87V 0.000000 N/A N/A 
9-10A F87I (24) 9-10A F87I 0.000983 -100 N/A 
9-10A F87L (24) 9-10A F87L 0.000710 -100 N/A 
9-10A T88C (24) 9-10A T88C 0.002516 -77 3 
9-10A T260S 
(24) 9-10A T260S 0.004259 -82 -6 
9-10A T260N 
(24) 9-10A T260N 0.003882 -77 15 
9-10A T260L 
(24) 9-10A T260L 0.006173 -77 -2 
9-10A A328V 
(22) 9-10A A328V 0.006471 -68 -8 
9-10A A328M 
(24) 9-10A A328M 0.005180 -82 6 
9-10A A328F 
(24) 9-10A A328F 0.002009 -63 -32 
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49-1A 
R47C, V78T, A82G, F87V, 
K94I, P142S, T175I, A184V, 
F205C, S226R, H236Q, 
E252G, R255S, A290V, 
A328L, L353V 
0.001874 -75 -32 
35-7F 
R47C, V78F, A82S, K94I, 
P142S, T175I, A184V, F205C, 
S226R, H236Q, E252G, 
R255S, A290V, A328L, 
L353V 
0.004514 -73 -52 
53-5H (24) 9-10A A78F, A82S, A328F 0.002840 -80 2 
7-11D 9-10A A82F, A328V 0.036840 -24 -28 
49-9B 
R47C, V78A, A82G, F87V, 
K94I, P142S, T175I, A184V, 
F205C, S226R, H236Q, 
E252G, R255S, A290V, 
A328L, L353V 
0.000000 N/A N/A 
41-5B 
R47C, V78F, A82G, K94I, 
P142S, T175I, A184V, F205C, 
S226R, H236Q, E252G, 
R255S, A290V, A328V, 
L353V 
0.008391 -77 -17 
13-7C (24) 9-10A A78T, A328L 0.005493 -73 -43 
12-10C 
R47C, V78A, A82G, F87V, 
K94I, P142S, T175I, A184V, 
F205C, S226R, H236Q, 
E252G, R255S, A290V, 
A328V, L353V 
0.004566 -73 -21 
77-9H (24) 9-10A A78T, A82G, A328L 0.003053 -73 -34 
11-8E 
R47C, V78A, F87V, K94I, 
P142S, T175I, A184V, F205C, 
S226R, H236Q, E252G, 
R255S, A290V, A328L, 
L353V 
0.001453 -77 15 
1-12G (22) 9-10A A82L, A328V 0.003884 -70 -19 
29-3E 
R47C, V78A, A82F, K94I, 
P142S, T175I, A184V, F205C, 
S226R, H236Q, E252G, 
R255S, A290V, A328F, 
L353V 
0.003425 -80 15 
29-10E 
R47C, V78F, A82G, K94I, 
P142S, T175I, A184V, F205C, 
S226R, H236Q, E252G, 
R255S, A290V, A328F, 
L353V 
0.001935 -70 16 
68-8F (24) 9-10A A78F, A82G, A328L 0.004127 -72 -32 
35E11 (25) 
R47C, V78F, A82S, K94I, 
P142S, T175I, A184V, F205C, 
S226R, H236Q, E252G, 
R255S, A290V, A328F, 
L353V, E464G, I710T 
0.003600 -71 -14 
19A12 (25) 35E11 L52I, L188P, I366V 0.006909 -70 -27 
ETS8 (25) 35E11 L52I, I366V 0.003966 -79 -19 
(11-3) (25) 35E11 L52I, A74S, L188P, I366V 0.005633 -76 -39 
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(7-7) (25) 35E11 L52I, A74E, S82G, A184V, L188P, I366V 0.010499 -77 -9 
H2A10 9-10A TS F87V, L75A, L181A, T268A 0.066422 -8 -94 
SL2-6F8 
R47C, L52I, V78F, A82S, 
K94I, P142S,T175I, A184V, 
F205C, S226R, H236Q, 
E252G, R255S, A290V, 
A328L, K349N, L353V, 
I366V, E464G, I710T 
0.000778 -100 N/A 
A12SL-17-4 
R47C, L52I, A74E, V78F, 
A82S, K94I, P142S,T175I, 
A184V, L188P, F205C, 
S226R, H236Q, E252G, 
R255S, A290V, A328F, 
L353V, I366V, E464G, I710T 
0.010935 -80 6 
H2-2-A1 (26) 9-10A TS F87V, L75A, L181A, L437A 0.003042 -75 -11 
A12RM-2-8 
R47C, L52I, A74E, V78F, 
A82S, K94I, P142S,T175I, 
A184S, L188P, F205C, S226R, 
H236Q, E252G, R255S, 
A290V, A328F, L353V, 
I366V, E464G, I710T 
0.007705 -77 -13 
H2-5-F10 9-10A TS F87V, L75A, I263A, T268A, L437A 0.141237 -46 -56 
13C9R1 
L52I, I58V, L75R, F87A, 
H100R, S106R, F107L, 
A135S, A184V, N239H, 
S274T, L324I, V340M, I366V, 
K434E, E442K, V446I 
0.001980 -100 N/A 
22A3 13C9R1 F162I E434K K442E I446V 0.004053 -70 4 
2C6 (27) 9-10A A78L, F87A, V184T, G315S, A330V 0.004257 -78 -15 
9C7 (27) 
9-10A C47R, A78L, F87G, 
I94K, A180V, V184T, G315S, 
A330V, Y345C 
0.007258 -79 -5 
B1 (27) 
9-10A C47R, A78L, F87A, 
I94K, V184T, I263M, G315S, 
A330V 
0.002246 -61 -14 
B1SYN (27) 
9-10A C47S, N70Y, A78L, 
F87A, I174N, I94K, V184T, 
I263M, G315S, A330V 
0.002705 -76 -23 
H2-4-D4 
9-10A TS F87V, L75A, 
M177A, L181A, T268A, 
L437A 
0.052439 57 -84 
E12 A87V (27) 
9-10A C47R, A78L, F87V, 
I94K, A111V, V141I, A180V, 
V184T, G315S, A330V 
0.001990 -65 -52 
GlcA4 T180A 9-10A C47R, F81W, A82S, F87A, I94K 0.004925 -78 12 
H2-8-C7 (26) 9-10A TS F87V, L75A, L181A 0.000808 -100 N/A 
CH-F8 9-10A L51A, C47A, F87V, 0.001126 -100 N/A 
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I94K, L181A, C205F, S254R, 
I366V, L437A, E442K 
H2-4-H5 (26) 9-10A TS F87V, L75A, M177A, L181A 0.001229 -100 N/A 
SA9 9-10A C47R, F81W, A82I, F87A, I94K, A180T, A197V 0.004170 -81 11 
ManA10 9-10A C47R, F81S, A82V, F87A, I94K, A180T, A197V 0.006340 -82 14 
Man1 9-10A C47R, F81L, A82T, F87A, I94K 0.003053 -73 21 
MB2 9-10A C47R, F81W, A82I, F87A, I94K 0.003282 -77 10 
HA62 9-10A C47R, F81A, A82L, F87A, I94K 0.003375 -81 -5 
9-10A TS 
V78A, P142S, T175I, A184V, 
S226R, H236Q, E252G, 
A290V, L353V, I366V, 
E442K 
0.001920 -75 -54 
9-10A TS F87A 9-10A TS F87A 0.001546 -60 5 
25F7 9-10A C47R, A74F, A78S, F87A, I282K, C205F, S255R 0.001829 -81 43 
24C4 9-10A C47R, A74I, A78L, F87A, I94K, C205F, S255R 0.000783 -100 N/A 
5A1 
9-10A M30T, C47R, A74F, 
A78S, I94K, C205F, S255R, 
Q310L, I366V, E442K 
0.002471 -80 15 
8B3 
9-10A M30T, C47R, A74F, 
A78S, I94K, C205F, C255R, 
L310Q, Q323L, I366V, 
N381K, R398H, E441K 
0.001315 -100 N/A 
 
* Reported as the sum of the area of the cyclopropane peaks over the area of the internal 
standard. † Diastereomeric excess = ([cis]-[trans])/([cis]+[trans]). ‡ (R,S) – (S,R). 
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Table S6: Raw GC screening data for the chimeric P450s in the compilation plate 
 
P450 chimeric P450s (heme domain block sequence) 
absolute 
activity* de
† ee (cis) ‡ 
CYP102A1 
(P450BM3) F87A 
(28) 
11111111 0.001704 -28 56 
CYP102A2 
F88A (28) 22222222 N/A N/A N/A 
CYP102A3 
F88A (28) 33333333 N/A N/A N/A 
5R1 (29) 32312231 0.008625 58 19 
9R1 (29) 12112333 0.0042707 58 24 
12R1 (29) 12112333 0.0701514 32 -49 
C1D11R1 (29) 21113312 0.007138 51 9 
C2B12R1 (29) 32313233 0.005914 38 -5 
C2C12R1 (29) 21313111 0.006226 28 9 
C2E6R1 (29) 11113311 0.008731 25 6 
C2G9R1 (29) 22213132 0.007975 15 31 
C3D10R1 (29) 22132231 0.004898 -16 -2 
C3E4R1 (29) 21313311 0.007893 14 17 
F3H12R1 (29) 21333233 0.005586 -56 -17 
F6D8R1 (29) 22313233 0.008088 -76 -6 
C3B5R1 (29) 23132233 0.014722 -81 4 
X7R1 (29) 22312333 0.017305 -4 -34 
 
* Reported as the sum of the area of the cyclopropane peaks over the area of the internal 
standard. † Diastereomeric excess = ([cis]-[trans])/([cis]+[trans]). ‡ (R,S) – (S,R). 
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Determining the cyclopropanation activity of the top 10 hits (highlighted in yellow 
on tables S5-6) under anaerobic conditions. Small-scale reactions (400 µL total 
volume) were conducted as described in section II and were analyzed by GC (cyclosil-B 
30 m x 0.32 mm x 0.25 µm): oven temperature = 100 °C 5 min, 1 °C / min to 135 °C, 135 
°C 10 min, 10 °C / min to 200 °C, 200 °C 5 min, cis-cyclopropanes (39.40 min and 40.20 
min), trans-cyclopropanes (44.69 min and 45.00 min). 
 
 
 
Table S7: Stereoselective P450BM3-based cyclopropanation catalysts 
 
P450 % yield* TTN cis : trans† %ee cis‡ %ee trans§ 
WT 1 5 37 : 63 -10 -9 
WTF87A 1.2 6 37 : 63 26 -6 
H2A10 33.4 167 60 : 40 -95 -78 
H2-4-D4 41.2 206 53 : 47 -79 -33 
H2-5-F10 58.8 294 16 : 84 -41 -63 
C2C12R1 1.6 8 36 : 64 45 1 
C3E4R1 1.6 8 43 : 57 51 -7 
X7R1 2.4 12 33 : 67 23 -4 
12 R1 6.2 31 17 : 83 9 -2 
C2E6 R1 4.6 23 27 : 73 25 -6 
C2G9 R1 48 240 9 : 91 10 -2 
7-11D 32 160 35 : 65 -22 -18 
 
* based on EDA. †	  Diastereomeric ratios and enantiomeric excess were determined by GC 
analysis. ‡ (R,S) – (S,R). § (R,R) – (S,S).  
 
OEt
O
N
N
+ + P450
0.1 M KPi pH 8.0
5% MeOH
10 mM Na2S2O4
30 mM 10 mM
Ph COOEt Ph COOEt
SSS R
COOEt
R R
Ph
R S
COOEtPh
+
cis trans
20 µM
0.2% mol eq
(wrt EDA)
Anaerobic
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V. Experimental Characterization of P450BM3 Cyclopropanation 
Catalysts 
 
V.I. Controls to confirm the enzymatic cyclopropanation activity of variant H2A10. 
Small-scale reactions (400 µL total volume) were set up and worked up as described in 
section II. For the carbon monoxide (CO) inhibition experiment, the reaction vial and the 
buffer/reductant vial were purged with CO after having been purged with argon. For the 
boiled P450 experiment, a 100 µM solution of variant H2A10 was heated at 60 °C for 10 
min. For the hemin experiment, hemin (80 µL) was added from a 1 mM solution in 50% 
DMSO-H2O, such that its final concentration in the reaction was 200 µM. Complete 
System = 10 mM styrene, 20 mM EDA, 20 mM Na2S2O4, 20 µM P450 (H2A10) under 
anaerobic conditions. The dried ethyl acetate extracts were analyzed by chiral phase GC, 
using 2-phenylethanol as an internal standard (injector temperature = 300 °C, oven 
temperature = 100 °C for 5 min, 1 °C / min ramp up to 135 °C, 135 °C for 10 min, 10 °C 
/ min ramp up to 200 °C, 200 °C for 5 min). Elution time: cis-cyclopropanes (39.40 min 
and 40.20 min), trans-cyclopropanes (44.69 min and 45.00 min).   
 
 
Table S8: Controls for P450 based cyclopropanation using variant H2A10 
 
conditions TTN % inhibition cis : trans* % ee cis† % ee trans‡ 
complete system (CS) 101 - 70 : 30 -95 -78 
CS-Na2S2O4+NADPH 45 -55 61 : 39 -87 -31 
CS-Na2S2O4+NADH 38 -62 53 : 47 -76 -19 
CS-Na2S2O4 0 -100 - - - 
CS-P450 0 -100 - - - 
CS+CO 0 -100 - - - 
boiled P450 146 +45 16 : 84 2 -2 
H2A10heme 85 -16 67 : 33 -92 -67 
CS-P450+hemin 16 -84 15 : 85 -1 -2 
CS (aerobic) 43 -57 67 : 33 -94 -76 *	  Diastereomeric ratios and enantiomeric excess were determined by GC analysis. † (R,S) 
– (S,R). ‡ (R,R) – (S,S).  
OEt
O
N
N
+ + P450
H2A10holo
0.1 M KPi pH 8.0
5% MeOH
10 mM Na2S2O4
10 mM 20 mM
Ph COOEt Ph COOEt
SSS R
COOEt
R R
Ph
R S
COOEtPh
+
cis trans
20 µM
0.2% mol eq
(wrt styrene)
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V.II. Optimizing cyclopropanation reaction conditions for variant H2A10. Small-
scale reactions (400 µL final volume) were set up and worked up as described in section 
II. The dried ethyl acetate extracts were analyzed by chiral phase GC, using 2-
phenylethanol as an internal standard (injector temperature = 300 °C, oven temperature = 
100 °C for 5 min, 5 °C / min ramp up to 200 °C, 20 °C / min ramp up to 250 °C, 250 °C 
for 5 min). Elution time: cis-cyclopropanes (19.20 min and 19.33 min), trans-
cyclopropanes (20.44 min). The reaction conditions that gave optimal yields of 
cyclopropanes (with respect to EDA) were: 30 mM styrene, 10 mM EDA and 20 µM 
P450 and were used in subsequent experiments.   
 
V.II.I. Styrene concentration 
 
 
 
 
Figure S1: Effect of styrene concentration on cyclopropane yield.  
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V.II.II. P450 concentration 
 
 
 
 
 
Figure S2: Effect of P450 (H2A10) concentration on cyclopropane yield  
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V.II.III. Dithionite concentration 
 
 
 
 
Table S9: Effect of concentration of Na2S2O4 on cyclopropane yield 
 
[Na2S2O4] / mM [cyclopropanes] / mM TTN 
0 0 0 
1 2.59 129 
5 2.72 136 
10 3.34 167 
20 3.13 156 
50 2.79 140 
100 2.71 136 
 
OEt
O
N
N
+ + Na2S2O4 + P450
H2A10holo
0.1 M KPi pH 8.0
5% MeOH
Ph
COOEt
20 mM 10 mM Variable
20 µM
0.2% mol eq 
(wrt EDA)
Anaerobic
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V.III. Mutational analysis of active site alanine substitutions in 9-10A TS F87V 
 
 
 
 
 
 
Table S10: Mutational analysis of alanine substitutions on 9-10A TS F87V 
 Mutations relative to 9-10A TS F87V      
P450 (Holo) L75A M177A L181A I263A T268A L437A TTN cis : trans* %ee cis† %ee trans‡ T50 (°C) 
9-10A TS F87V No No No No No No 7 35 : 65 -41 -8 59.5 
9-10A TS F87V 
L75A Yes No No No No No 5 42 : 58 -59 -11 52.3 
9-10ATS F87V 
L181A No No Yes No No No 5 41 : 59 -27 -7 53.3 
9-10A TS F87V 
I263A No No No Yes No No 8 29 : 71 -31 -39 55.4 
9-10A TS F87V 
T268A (BM3-CIS) No No No No Yes No 199 71 : 29 -94 -91 55.2 
BM3-CIS I263A No No No Yes Yes No 190 19 : 81 -62 -91 54.0 
BM3-CIS L181A No No Yes No Yes No 159 56 : 44 -92 -94 50.8 
H2A10 Yes No Yes No Yes No 167 60 : 40 -95 -78 48.9 
BM3-CIS L181A 
I263A No No Yes Yes Yes No 203 14 : 86 -46 -95 50.9 
BM3-CIS L181A 
L437A No No Yes No Yes Yes 180 27 : 73 -74 -98 48.4 
BM3-CIS L181A 
I263A L437A No No Yes Yes Yes Yes 218 9 : 91 -55 -96 48.2 
4H5 Yes Yes Yes No No No 7 32 : 68 -9 0 49.4 
BM3-CIS I263A 
L437A No No No Yes Yes Yes 267 16 : 84 -59 -89 50.4 
H2-5-F10 Yes No No Yes Yes Yes 294 16 : 84 -41 -63 47.5 
H2-4-D4 Yes Yes Yes No Yes Yes 206 53 : 47 -79 -33 46.4 
 *	  Diastereomeric ratios and enantiomeric excess were determined by GC analysis. † (R,S) 
– (S,R). ‡ (R,R) – (S,S).  
 
OEt
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N
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30 mM 10 mM
Ph COOEt Ph COOEt
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COOEt
R R
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R S
COOEtPh
+
cis trans
20 µM
0.2% mol eq
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V. IV. Sequential introduction of BM3-CIS active site mutations in wild-type 
P450BM3 
 
 
 
Table S11: Introducing BM3-CIS related active site mutations in wild-type P450BM3 
 
Mutations relative to wild-
type P450BM3 
 
    
P450 (Holo) V78 F87 T268 I263 TTN  cis : trans* %ee cis† %ee trans‡  T50 (°C) 
WT - - - - 5 37 : 63 -10 -9 56.0 
WT-F87A - A - - 6 38 : 62 26 -6 53.0 
WT-F87V - V - - 9 30 : 70 -33 -26 52.9 
WT-T268A - - A - 323 1 : 99 -15 -96 53.6 
WT-F87V/T268A - V A - 274 32 : 68 -77 -99 52.0 
WT-
V78A/F87V/T268A A V A - 190 32 : 68 -70 -20 50.8 
WT-
F87V/I263A/T268A - V A A 246 7 : 93 8 -94 50.0 	  *	  Diastereomeric ratios and enantiomeric excess were determined by GC analysis. † (R,S) 
– (S,R). ‡ (R,R) – (S,S).  
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cis trans
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VI. Active Site Saturation Mutagenesis of BM3-CISheme 
 
Library construction. To simplify library construction and screening, only the BM3-CIS 
heme domain, which comprises residues 1-462 was used. This truncated enzymes lacks 
the P450 native reductase and exhibits similar activity and stereochemical control to the 
full length enzyme using Na2S2O4 as a reductant, but not NADPH (data not shown). P450 
site-directed mutagenesis and site-saturation libraries were assembled from PCR 
fragments generated from oligonucleotides containing the desired codon mutation or a 
degenerate NNK (or for reverse primers, the reverse complement MNN; where N = 
A,T,G,C, K = G,T and M = A,C) codon, which codes for all 20 amino acids and the TAG 
stop codon. PCR fragments were assembled using either standard overlap extension PCR 
or through restriction cloning using the Type IIS restriction enzyme, BsaI, depending on 
convenience. 
 
Lysate screening under aerobic conditions. The compilation plate was expressed and 
lysed as described in section II (enzyme library screening). 150 µL lysate was 
transferred (Multimek 96-channel pipetting robot, Beckman Coulter, Fullerton, CA) to a 
2 mL deep-well plate, with 50 µL of 120 mM Na2S2O4 in 0.1 M KPi (pH = 8.0). 100 µL 
of a 90 mM styrene, 30 mM EDA mixed solution in 15% MeOH in 0.1 M KPi (pH = 8.0) 
was added to the plate to initiate the reaction. The plate was sealed and was left shaking 
(300 rpm) for four hours. The plastic seal was removed and 30 µL HCl (3 M) was added 
to quench the reaction followed by 20 µL of an internal standard solution (20 mM 2-
phenylethanol in methanol). Acetonitrile (400 µL) was added before carefully vortexing 
the plate. The plate was centrifuged (1,700xg), the supernatant was filtered (1 µm glass, 
96 well filter plate, Pall) and transferred (150 µL) to a 96-well microtiter plate (Agilent). 
Reactions were analyzed by reverse-phase HPLC (210 nm): 50% acetonitrile-water, 1.0 
mL min-1, cis-cyclopropanes (7.6 min), trans-cyclopropanes (9.7 min). Hits were selected 
based on enhancement of cis-selectivity over parent BM3-CIS. 
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Determining the cyclopropanation activity of hits from the site-saturation libraries 
under anaerobic conditions. Small-scale reactions (400 µL total volume) were 
conducted as described in section II and were analyzed by GC (cyclosil-B 30 m x 0.25 
mm x 0.25 µm): oven temperature = 130 °C, 175 kPa, cis-cyclopropanes (39.40 min and 
40.20 min), trans-cyclopropanes (44.69 min and 45.00 min). 
 
 
 
 
Table S12: Cyclopropanation activity of selected BM3-CISheme active site variants 
 
P450heme yield (%)* TTN cis : trans† %ee cis‡ %ee trans§ 
BM3-CIS 57 286 71 : 29 -92 -88 
BM3-CIS-L181G 47 234 59 : 41 -89 -90 
BM3-CIS-A328G 37 186 83 : 17 52 -45 
BM3-CIS-L437F 53 265 53 : 47 -82 -85 
BM3-CIS-L437Q 30 148 53 : 47 -73 -87 
BM3-CIS-L437G 58 290 54 : 46 -88 -91 
BM3-CIS-L437A 39 194 38 : 62 -84 -11 
BM3-CIS-T438A 54 273 91 : 9 -92 -75 
BM3-CIS-T438G 15 78 73 : 27 -87 -59 
BM3-CIS-T438S 59 293 92 : 8 -97 -66 
BM3-CIS-T438Q 41 206 38 : 62 67 70 
BM3-CIS-T438P 32 161 90 : 10 -91 -50 
 
* based on EDA. †	  Diastereomeric ratios and enantiomeric excess were determined by GC 
analysis. ‡ (R,S) – (S,R). § (R,R) – (S,S).  
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VII. Kinetic Characterization of BM3-CIS 
 
Determination of initial rates. Both styrene and EDA concentrations were varied in the 
presence of the P450s expressed as the heme-domain (0.5 or 1.0 µM BM3-CISheme). 
Reactions were set up in phosphate buffer (pH = 8.0) with Na2S2O4 as the reductant at 
298 K, and were worked-up as described in section II. Three time points were taken and 
used to determine the rate of product formation by GC (cyclosil-B 30 m x 0.32 mm x 
0.25 µm): oven temperature = 100 °C 5 min, 5 °C / min to 200 °C, 20 °C / min to 250 °C, 
250 °C for 5 min. Elution time: cis-cyclopropanes (19.20 min and 19.33 min), trans-
cyclopropanes (20.44 min). Kinetic parameters were determined by fitting the data to the 
standard Michaelis-Menten model.    
 
 
 
Figure S3: Initial velocities plot for BM3-CISheme. A) EDA concentration was varied at a 
saturating concentration of styrene (30 mM). B) Styrene concentration was varied at a 
fixed concentration of EDA (20 mM). Initial rates were computed as the slope of a zero-
intercept linear fit of three different time points from independent reactions. Error bars 
correspond to 1-σ (68.3%) confidence intervals for the slope. 
 
 
Table S13: Michaelis-Menten parameters for P450 cyclopropanation catalysts 
 
catalyst kcat (min-1) 
KM-EDA 
(mM) 
KM-styrene 
(mM) 
kcat / KM-
EDA (s-1 M-1) 
kcat / KM-
styrene 
(s-1 M-1) 
kcat / (KM-EDA x 
KM-styrene) 
(s-1 M-1 M-1) 
BM3-
CISheme 
100 ± 24 5.2 ± 3.5 1.4 ± 0.5 320 1,100 2.1 x 105 
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Table S14: Kinetic parameters for wild-type cytochrome P450s acting on their native 
substrates and for an engineered variant of P450BM3 (propane monooxygenase, PMO)  
acting on the non-native substrate propane 
 
P450 substrate kcat (min-1) KM (mM) kcat / KM (s
-1 
M-1) 
CYP153A6   
(30) octane 75 0.32 3,900 
P450BM3  
(31) lauric acid 5140 0.29 3.0 x 10
5 
PMO (32) propane 450 0.17 4.4 x 104 
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Table S15: Effect of EDA addition at t = 30 min on BM3-CIS-catalyzed 
cyclopropanations  
 
conditions TTN cis : trans* %ee cis † %ee trans‡ 
10 mM EDA added at t = 0 273 ± 2.5 72 : 28 -92 -90 
10 mM EDA added at t = 0  
+ 10 mM EDA at t = 30 min 425 ± 17 73 : 27 -93 -89 
 
TTN values are reported as the mean of triplicates ± standard deviation. * Diastereomeric 
ratios and enantiomeric excess were determined by GC analysis. † (R,S) – (S,R). ‡ (R,R) – 
(S,S) 
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VIII. Substrate Scope of P450 Cyclopropanation Catalysts 
 
Small-scale reactions. Selected P450 catalysts were surveyed at a small-scale (400 µL 
total volume) for each combination of reagents (olefins and diazo esters). The small-scale 
anaerobic bioconversions were conducted as described in section II and were analyzed by 
GC.  
 
 
 
Table S16: Substrate scope of P450 cyclopropanation catalysts: p-methylstyrene + EDA  
  
P450 % yield TTN cis : trans %ee cis %ee trans* 
7-11D 21 104 54 : 46 0.3 N/A 
H2-5-F10 44 222 11 : 89 14.9 N/A 
C2G9 R1 18 92 10 : 90 8.9 N/A 
H2A10 10 50 43 : 57 -84.3 N/A 
BM3-CIS 46 228 78 : 22 -81.4 N/A 
Hemin 7 37 6 : 94 -1.6 N/A 
 
GC (cyclosil-B column 30 m x 0.32 mm, 0.25 µm film): oven temperature = 100 °C for 5 
min, 5 °C / min to 200 °C, 20 °C / min to 250 °C, 250 °C for 5 min. Elution times: cis-
cyclopropanes (21.03 and 21.18 min), trans-cyclopropanes (22.71 min). * trans-
enantiomers did not resolve.  
 
  
OEt
O
N
N
+ + P450
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30 mM 10 mM
20 µM
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(0.2 mol%)
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Table S17: Substrate scope of P450 cyclopropanation catalysts: p-vinylanisole + EDA 
   
P450 % yield TTN cis : trans %ee cis %ee trans* 
7-11D 59 297 70 : 30 -27 N/A 
H2-5-F10 73 364 11 : 89 38 N/A 
C2G9 R1 39 196 10 : 90 -1 N/A 
H2A10 16 80 40 : 60 -75 N/A 
BM3-CIS 43 214 48 : 52 -44 N/A 
hemin 19 96 7 : 93 0 N/A 
 
GC oven temperature = 110 °C for 8 min, 2 °C / min to 180 °C then 180 °C for 30 min, 
175 kPa. Cyclosil-B column (30 m x 0.25 mm, 0.25 µm film). Elution times: cis-
cyclopropanes (38.74 and  39.52 min), trans-cyclopropanes (43.07 min). * Baseline 
resolution could not be achieved for the trans-enantiomers. 
 
 
  
OEt
O
N
N
+ + P450
COOEt
30 mM 10 mM
20 µM
(0.2 mol%)
AnaerobicMeO
MeO
0.1 M KPi pH 8.0
5% MeOH
10 mM Na2S2O4
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Table S18: Substrate scope of P450 cyclopropanation catalysts: p-
(trifluoromethyl)styrene  
 
P450 % yield* TTN* cis : trans %ee cis %ee trans 
7-11D 24 120 76 : 24 31 59 
H2-5-F10 40 198 26 : 74 72 -65 
C2G9 R1 18 89 10 : 90 4 0 
H2A10 9 47 26 : 74 -24 22 
BM3-CIS 42 211 39 : 61 54 -93 
hemin 2 9 11 : 89 1 1 
 
* Assumed the same detector response factor as for ethyl 2-(4-
methylphenyl)cyclopropane-1-carboxylate. GC (cyclosil-B column 30 m x 0.25 mm, 0.25 
µm film): oven temperature = 110 °C for 8 min, 2 °C / min to 180 °C then 180 °C for 30 
min, 175 kPa. Elution times: cis-cyclopropanes (27.26 and  28.11 min), trans-
cyclopropanes (30.78 and 30.99 min).  
  
OEt
O
N
N
+ + P450
COOEt
30 mM 10 mM 20 µM
(0.2% mol eq)
AnaerobicF3C
F3C
0.1 M KPi pH 8.0
5% MeOH
10 mM Na2S2O4
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Table S19: Substrate scope of P450 cyclopropanation catalysts: α-methyl styrene 
   
P450 % yield TTN Z : E %ee (Z) %ee (E) * 
7-11D 31 157 41 : 49 42 N/A 
H2-5-F10 66 329 21 : 79 -14  N/A 
C2G9 R1 77 387 16 : 84 -4 N/A 
H2A10 34 168 19 : 81 -31 N/A 
BM3-CIS 26 127 16 : 84 -6 N/A 
WT F87V T268A 62 312 7 : 93 3 N/A 
hemin 15 77 24 : 76 0 N/A 
 
GC oven temperature = 100 °C for 5 min, 1 °C / min up to 135 °C, 135 °C for 10 min, 10 
°C / min up to 200 °C, 200 °C for 5 min. Cyclosil-B column (30 m x 0.32 mm, 0.25 µm 
film). Elution times: Z-cyclopropanes (34.96 and 35.33 min), E-cyclopropanes (39.34 and 
39.61 min). * trans-enantiomers did not separate to baseline resolution. 
  
OEt
O
N
N
+ + P450
30 mM 10 mM
20 µM
(0.2% mol eq)
Anaerobic
0.1 M KPi pH 8.0
5% MeOH
10 mM Na2S2O4
COOEtPh
Me
PhEtOOC
Me
(Z)
COOEtMe
Ph
MeEtOOC
Ph (E)
	  
 
 32	  
 
 
Table S20:  Substrate scope of P450 cyclopropanation catalysts: t-butyl diazoacetate  
  
P450 % yield* TTN* cis : trans 
WT F87V 
T268A 1.4 7 4 : 96 
7-11D 11 54 13 : 87 
H2-5-F10 18 90 3 : 97 
H2A10 24 120 3 : 97 
BM3-CIS 0.3 2 3 : 97 
hemin 20 100 4 : 96 
 
* Assumed the same detector response factor as for ethyl 2-(4-
methylphenyl)cyclopropane-1-carboxylate. GC (cyclosil-B column 30 m x 0.32 mm, 0.25 
µm film): oven temperature = 100 °C for 5 min, 5 °C / min to 200 °C, 20 °C / min to 250 
°C, 250 °C for 5 min. Elution times: cis-cyclopropanes (21.66 min), trans-cyclopropanes 
(23.31 min). Cis- and trans-enantiomers did not resolve. 
 
 
  
O
O
N
N
+ + P450
0.1 M KPi pH 8.0
5% MeOH
10 mM Na2S2O4
30 mM 10 mM
20 µM
Anaerobic
(0.2 mol%)
O
O
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Preparative-scale bioconversions. These reactions were conducted anaerobically as 
described in section II.  
 
Cyclopropanation of styrene with EDA  
 
 
 
Prepared using 1.5 mmol styrene (3 equiv), 0.5 mmol EDA (1 equiv) and 1 µmol BM3-
CISheme (0.002 equiv). The product was purified by SiO2 chromatography (9:1 hexanes-
diethyl ether) to give 25 mg of the cis-cyclopropane (1) and 8 mg of a mixture of 
cyclopropanes with trans (2) in 5 : 1 excess over cis (33-35). Diagnostic data for the cis-
cyclopropane 1: 1H NMR (CDCl3, 500 MHz): δ 7.28 (m, 4H), 7.21 (m, 1H), 3.89 (q, J = 
7.1 Hz, 2H), 2.60 (m, 1H), 2.10 (m, 1H), 1.73 (m, 1H), 1.35 (m, 1H), 0.99 (t, J = 7.1 Hz, 
3H); 13C NMR (CDCl3, 125 MHz): δ 170.99, 136.56, 129.31, 127.88, 126.63, 60.18, 
25.47, 21.80, 14.02, 11.12; [α]25D = - 7.056° (c 0.83, CHCl3). Diagnostic data for the 
trans-cyclopropane 2: 1H NMR (CDCl3, 500 MHz): δ 7.20 (m, 3H), 7.03 (m, 2H), 4.10 
(q, J = 7.1 Hz, 2H), 2.45 (m, 1H), 1.83 (m, 1H), 1.53 (m, 1H), 1.23 (m, 1H), 1.21 (t, J = 
7.1 Hz, 3H); 13C NMR  (CDCl3, 125 MHz): δ 173.43, 140.13, 128.46, 126.55, 126.16, 
60.72, 26.18, 24.20, 17.09, 14.27; [α]25D = + 199.2° (c 0.50, CHCl3). MS (EI+) m/z: 190 
(M+), 162 (PhCH(CH2)CHCO2+), 145 (PhCH(CH2)CHCO+). The absolute configuration 
of compounds 1 and 2 was determined by comparison of the sign of their optical rotations 
with that reported (19). The enantiomeric excess was determined to be 92% for the cis-
cyclopropane and 88% for the trans-cyclopropane by GC. 
 
 
Cyclopropanation of p-methylstyrene with EDA 
 
 
Prepared using 1.5 mmol styrene (3 equiv), 0.5 mmol EDA (1 equiv) and 1 µmol BM3-
CISheme (0.002 equiv). The product was purified by SiO2 chromatography (9:1 hexanes-
diethyl ether) to give 10 mg of the cis-cyclopropane (3) and 16 mg of a mixture of 
cyclopropanes with trans(4) : cis / 2 : 1 (35). Diagnostic data for the cis-cyclopropane 3: 
1H NMR (CDCl3, 500 MHz): δ 7.17 (d, J = 8.0 Hz, 2H), 7.08 (d, J = 8.0 Hz, 2H), 3.91 (q, 
J = 7.1 Hz, 2H), 2.56 (m, 1H), 2.32 (s, 3H) 2.06 (m, 1H), 1.69 (m, 1H), 1.32 (m, 1H), 
1.02 (t, J = 7.1 Hz, 3H); 13C NMR (CDCl3, 125 MHz): δ 171.12, 136.12, 133.42, 129.14, 
N2 CO2Et+
0.2mol% C3C
0.1 M KPi pH 8, 5% MeOH
10 mM Na2S2O4
35%
Ph CO2Et
(S) (R)
Ph CO2Et
(S) (S)+
1 2(76:24)
92%ee 88%ee
BM3-CISheme
N2 CO2Et+
0.2mol% C3C
0.1 M KPi pH 8, 5% MeOH
10 mM Na2S2O4
25%
CO2Et CO2Et
+
3 4
(80:20)
82%ee
BM3-CISheme
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128.60, 60.17, 25.23, 21.68, 21.10, 14.08, 11.21. Diagnostic data for the trans-
cyclopropane 4: 1H NMR (CDCl3, 500 MHz): δ 7.09 (d, J = 8.0 Hz, 2H), 7.01 (d, J = 8.0 
Hz, 2H), 4.19 (q, J = 7.1 Hz, 2H), 2.50 (m, 1H), 2.33 (s, 3H), 1.88 (m, 1H), 1.59 (m, 1H), 
1.33 (m, 1H), 1.29 (t, J = 7.1 Hz, 3H); 13C NMR  (CDCl3, 125 MHz): δ 173.58, 137.04, 
136.08, 129.12, 126.10, 60.66, 25.94, 24.06, 21.11, 16.96, 14.28. MS (EI+) m/z: 204 
(M+), 175 ([M-Et]+) 131 ([M-COOEt]+). The enantiomeric excess was determined to be 
82% for the cis-cyclopropane by GC. Baseline resolution of the trans-enantiomers could 
not be achieved.  
 
Cyclopropanation of p-methoxystyrene with EDA 
 
 
Prepared using 1.5 mmol styrene (3 equiv), 0.5 mmol EDA (1 equiv) and 1 µmol BM3-
CISheme (0.002 equiv). The product was purified by SiO2 chromatography (9:1 hexanes-
diethyl ether) to give 16 mg of the trans-cyclopropane (6) and 3 mg of a mixture of 
cyclopropanes with cis : trans / 5 : 1 (35). Diagnostic data for the trans-cyclopropane 6: 
6.96 (m, 3H), 6.75 (m, 2H), 4.09 (q, J = 7.1 Hz, 2H), 3.72 (s, 3H), 2.41 (m, 1H), 1.75 (m, 
1H), 1.48 (m, 1H), 1.21 (t, J = 7.1 Hz, 3H), 1.18 (m, 1H). MS (EI+) m/z: 220 (M+), 191 
([M-Et]+), 175 ([M-EtO]+), 147 ([M-COOEt]+). The enantiomeric excess was determined 
to be 38% for the cis-cyclopropane by GC. The trans-enantiomers did not resolve to 
baseline resolution.  
 
Cyclopropanation of styrene with t-butyl diazo acetate 
 
 
Prepared using 0.75 mmol styrene (3 equiv), 0.24 mmol t-BuDA (1 equiv) and 0.5 µmol 
BM3-CISheme (0.002 equiv). The product was purified by SiO2 chromatography (9:1 
hexanes-diethyl ether) to give 9 mg of the trans-cyclopropane (8) (33, 35). Diagnostic 
data for the trans-cyclopropane 4: 1H NMR (CDCl3, 500 MHz): δ 7.20 (m, 2H), 7.12 (m, 
1H), 7.02 (m, 2H), 2.36 (m, 1H), 1.76 (m, 1H), 1.45 (m, 1H), 1.40 (s, 9H), 1.16 (m, 1H); 
13C NMR (CDCl3, 125 MHz): δ 172.58, 140.52, 128.42, 126.32, 126.07, 80.57, 28.17, 
25.75, 25.31, 17.08. MS (EI+) m/z: 218 (M+), 145 ([M-OtBu]+).    
  
N2 CO2Et+
0.2mol% H2-5-F10
0.1 M KPi pH 8, 5% MeOH
10 mM Na2S2O4
40%
CO2Et CO2Et
+
5 6
(10:90)
MeO
MeO MeO
38%ee
N2 CO2t-Bu+
0.2mol% H2-5-F10
0.1 M KPi pH 8, 5% MeOH
10 mM Na2S2O4
17%
Ph CO2t-Bu Ph CO2t-Bu
+
7 8(3:97)
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IX. Summary of mutations in P450BM3 variants 
Mutations in variant P450 cyclopropanation catalysts are reported with respect to wild-
type P450BM3. 
 
7-11D (24): R47C, V78A, K94I, P142S, T175I, A184V, F205C, S226R, H236Q, E252G, 
R255S, A290V, L353V, A82F, A328V  
 
9-10A TS (26): V78A, P142S, T175I, A184V, S226R, H236Q, E252G, A290V, L353V, 
I366V, E442K 
 
H2A10: 9-10A TS + F87V, L75A, L181A, T268A 
 
H2-5-F10: 9-10A TS + F87V, L75A, I263A, T268A, L437A 
 
H2-4-D4: 9-10A TS + F87V, L75A, M177A, L181A, T268A, L437A 
 
BM3-CIS: 9-10A TS + F87V, T268A 
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